by MM360 Staff | May 28, 2025 | Uncategorized
Source: CureToday articles ATR-04 therapy is being investigated in the phase 1/2 ATR04-484 clinical trial for the treatment of EGFR inhibitor-associated rashes in lung cancer. Read More
by MM360 Staff | May 28, 2025 | Myeloma News
Source: Pharmacy Times articles Corrine Stahura, PharmD, and Sophia Gilardone, PharmD, BCOP, discuss how patient- and treatment-related factors influence the risk of severe toxicity with antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC). Read...
by MM360 Staff | May 28, 2025 | Myeloma News
Source: Pharmacy Times articles Grace Nguyen, PharmD, BCPS, provides real-world experiences with DPYD genotype-guided fluoropyrimidine dosing, highlighting how pharmacist-led interventions and tailored dose adjustments can help mitigate toxicity risks and optimize...
by MM360 Staff | May 28, 2025 | Myeloma News
Source: Pharmacy Times articles Derek Webb, PharmD, a community pharmacist and Virginia Board of Pharmacy member, provides comprehensive guidance on managing seasonal allergies, distinguishing between symptoms, and exploring treatment options for patients. Read...
by MM360 Staff | May 28, 2025 | Myeloma News
Source: Pharmacy Times articles Integrated health system specialty pharmacies can improve patient care for non–multiple sclerosis neurologic conditions. Read More
